Greenwich LifeSciences, Inc. (GLSI) Stock Ticker
GLSI right now
Market factors today
Unlock the full GLSI picture
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.
GLSI stock facts
| Ticker symbol | GLSI |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $267.4M |
| CEO | Snehal S. Patel |
| Employees | 13 |
| Headquarters | Stafford, TX, US |
| IPO date | 2020-09-25 |
| Website | greenwichlifesciences.com |
What you can see for GLSI on Tickr
Live GLSI price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the GLSI report.
Rankings
FAQ
What is the ticker symbol for Greenwich LifeSciences, Inc.?
The ticker symbol for Greenwich LifeSciences, Inc. is GLSI, listed on the NASDAQ Capital Market.
What is GLSI?
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to…